LBI-HTA - Publications - Search - Subject: WP 800-910 Breast
Number of items at this level: 41.

Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for the Treatment of Breast Cancer. Decision Support Document 57.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.

Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.

Jonas, S. and Schamberger, C. and Wild, C. (2002): [Predictive genetic diagnosis for breast and colon carcinoma: Diagnosis, treatment, public health aspects]. ITA-Projektbericht 21.

Jonas, S. and Wild, C. and Schamberger, C. (2003): [Predictive genetic testing for breast and colorectal cancer]. ZaeFQ: Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 97 (01): 67-71.

Jonas, S. and Wild, C. and Schamberger, C. (2002): Predictive genetic testing for mammary and colorectal cancer. Wiener Klinische Wochenschrift 114 Suppl. (17-18): 24.

Kirisits, A. and Wild, C. (2012): Efficacy of Hyperthermia Treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix Carcinoma and Soft Tissue Sarcoma patients. Update 2012. Decision Support Document 36 / Update 2012.

Korencan, A. (2007): [HER2 diagnostics in breast cancer]. HTA-Newsletter 55: 3-4.

Korencan, A. and Guba, B. and Wild, C. (2007): Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice. HTA-Projektbericht 08.

Mathis, S. and Garbaty , T. and Czeczot , J. and Maran , P.R. and Alberti, C. and Nachtnebel, A. (2011): Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 18.

McGahan, L. (2017): Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. DSD: Horizon Scanning in Oncology 64.

Nachtnebel, A. (2012): Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer. DSD: Horizon Scanning in Oncology 31.

Nachtnebel, A. (2010): Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 09.

Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.

Patera, N. and Wild, C. (2009): Status quo mammography screening: evaluation results from organised programs. HTA-Projektbericht 035.

Radlberger, P. (2006): [Predictive genetic diagnostics: Testing for breast cancer]. HTA-Newsletter 52: 2.

Radlberger, P. (2006): [Magnetic resonance imaging in patients with breast cancer]. HTA-Newsletter 51: 2-3.

Radlberger, P. and Wild, C. and Guba, B. (2007): [Mammography screening. Evidence-based evaluation of mammography-based breast cancer screening programmes]. HTA-Projektbericht 07.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Schiller-Frühwirth, I. and Wild, C. (2012): Intraoperative radiotherapy for primary breast cancer. Decision Support Document 23 / Update 2012.

Schiller-Frühwirth, I. and Wild, C. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Intraoperative radiotherapy for primary breast cancer. Systematic Review.. Decision Support Document 23.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: 4.

Wild, C. (2005): [Proton therapy]. HTA-Newsletter 43: 3.

Wild, C. (2005): [Herceptin®/Trastuzumab for metastatic breast cancer]. HTA-Newsletter 40: 3.

Wild, C. (2005): [Computer-aided detection (CAD) in mammography]. HTA-Newsletter 37: 2-3.

Wild, C. (2004): [Breast cancer care: Quality indicators]. HTA-Newsletter 32: 4.

Wild, C. (2004): [Sentinel node biopsy (SNB) in breast cancer]. HTA-Newsletter 24: 2-3.

Wild, C. (2004): [Intraoperative radiotherapy in early stage breast cancer]. HTA-Newsletter 24: 4.

Wild, C. (2004): [Mammography screening in Austria. Editorial]. HTA-Newsletter 24: 1-2.

Wild, C. (2004): [Breast cancer diagnosis by magnetic resonance imaging or positron emission tomography (PET)]. HTA-Newsletter 24: 3-4.

Wild, C. (2004): [Epithelial cell cytology in breast cancer risk assessment]. HTA-Newsletter 24: 2.

Wild, C. (2003): [High-dose chemotherapy]. HTA-Newsletter 22: 4.

Wild, C. (2003): [Patient information in screening programmes. Editorial]. HTA-Newsletter 18: 1-2.

Wild, C. (2003): [Digital mammography/DM]. HTA-Newsletter 15: 2-3.

Wild, C. (2002): [Trastuzumab for breast cancer]. HTA-Newsletter 12: 2.

Wild, C. (2002): [Predictive genetic testing for breast and prostate cancer]. HTA-Newsletter 07: 2.

Wild, C. (2001): Screening in Austria - the cases of mammography, PSA-testing and routine use of ultrasonography in pregnancy. International Journal of Technology Assessment in Health Care 17 (03): 305-315.

Wild, C. and Jonas, S. (2002): [Predictive genetic testing for breast and colon cancer]. Newsletter der Österreichischen Gesellschaft für Public Health (3): 1.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

This list was generated on Sat Jun 24 14:00:45 2017 CEST.